CFN Media

February 13, 2017 09:20 ET

Lexaria Expands Scope with National Research Council Agreement -- CFN Media

SEATTLE, WA--(Marketwired - Feb 13, 2017) - CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article discussing Lexaria Bioscience Corp.'s (OTCQB: LXRP) recent collaboration agreement with the National Research Council of Canada, and the impact it could have on the development of Lexaria's groundbreaking lipid delivery technology.

Lexaria has been quietly developing an innovative delivery system that has the potential to revolutionize several industries. By encapsulating active ingredients in a lipid, the technology enhances the bioavailability of the active compound by facilitating it into the intestinal tract while eliminating any negative tastes or textures. The technology is patent-pending for use with both cannabinoids and anti-inflammatory drugs ("NSAIDS").

Lexaria's master collaborative research agreement with the National Research Council of Canada ("NRC") opens several doors for its innovative delivery technology. For example, the company does not have the permits needed to explore the potential implications of its technology on tetrahydrocannabinol ("THC") related products. The NRC is a governmental organization that has the rights to work with THC and other controlled substances.

The agreement also provides funding to better understand how the technology works to improve bioavailability. Under the terms, Lexaria and the NRC will both provide up to C$125,000 in funding for a total investment of up to C$250,000 over 18 months. The collaboration will investigate and define the chemical nature of the molecular association that the technology leverages in order to increase the bioavailability of various substances.

The researchers will evaluate cannabinoids (including THC), fat-soluble vitamins, non-steroidal anti-inflammatory drugs, and nicotine, as described in Lexaria's issued and pending patent applications, and could grow that list with other high value bioactives to be determined. The agreement also provides for possible licensing of any arising, non-competing intellectual property to the NRC or its sub-licensees on terms to be defined in the future.

Management sees the potential to attract licensees across several end markets, including the therapeutic foods, dietary supplements, and pharmaceutical sectors. Through these markets, the company could launch a wide range of products to consumers including over-the-counter pain remedies, vitamins and supplements, and even smoking cessation products.

Please follow the link to read the full article:

Learn how to become a CFN Media client company, brand or entrepreneur:

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:

About CFN Media

CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.

CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information